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Abstract 
Secondary structure prediction studies on CAP18, a lipopolysaccharide binding protein from rabbit granulocytes, identified a highly cationic. 
21-residue sequence with the tendency to adopt an amphipathic a-helical conformation, as observed in many antimicrobial peptides. The correspond- 
ing peptide was chemically synthesized and shown to exert a potent bactericidal activity against both Gram-negative and Gram-positive bacteria, 
and a rapid penneabilization of the inner membrane of Escherichla cob. Five analogues were synthesized to elucidate structure/activity relationships. 
It was found that helix disruption virtually eliminates antibacterial activity, while the degree of amphipathicity and the presence of an aromatic residue 
greatly affect the kinetics of bacterial inner membrane permeabilization. 
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1. Introduction 
A number of antimicrobial polypeptides involved in 
host defense have been isolated from various animal spe- 
cies [l-5]. In general, they are highly cationic and act by 
perturbing the membranes of target microorganisms. 
This perturbation very likely depends on the adoption of 
amphipathic onformations, such as those observed for 
cecropins [6], magainins [7], and defensins [8]. In mam- 
mals, the cytoplasmic granules of polymorphonuclear 
leukocytes are a major store of defense polypeptides, 
which show diverse primary structures and a varied spec- 
trum of antibacterial activity [2-51. 
Recent cloning of three structurally unrelated anti- 
bacterial peptides from bovine neutrophils have shown 
that their proforms share a highly conserved pro region 
[9-l 11. This region is remarkably homologous to cathe- 
lin, a cathepsin L inhibitor previously isolated from pig 
leukocytes [12,131, and has to be proteolytically removed 
to convert the inactive proform to the mature anti- 
bacterial peptide [14]. The presence of a cathelin-like 
region was also identified in two other polypeptides from 
rabbit neutrophils, namely CAP18 [9], from 18 kDa cat- 
ionic antimicrobial protein [15], and ~15, from 15 kDa 
protein [16]. CAP18 was reported to bind lipopolysac- 
charide (LPS) [17], but to our knowledge its antimicro- 
bial activity has not yet been described despite its name. 
By analogy with the bovine antibacterial peptides 
*Corresponding author. Fax: (39) (40) 676 3691. 
located C-terminal to a cathelin-like domain [9-l 11, we 
inspected the C-terminal region of CAP18 for features 
typical of antibacterial peptides. A highly cationic se- 
quence, corresponding to residues 106125, was identi- 
fied and predicted to assume an amphipathic a-helical 
conformation. These convergent indications induced us 
to synthesize the corresponding peptide and to test its 
antibacterial activity. 
In this paper we show that this synthetic peptide, 
termed C18, exerts a potent bactericidal activity against 
both Gram negative and Gram positive microorganisms, 
and a remarkable permabilizing effect on the inner mem- 
brane of E. coli. The bioactivity of five synthetic 
analogues of C18, designed to probe how structural 
characteristics, charge and individual residues affect its 
biological activity, is also reported. 
2. Materials and methods 
2.1. Materials 
Fmoc-amino acids and reagents for peptide synthesis were obtained 
from Millipore (Bedford, USA) and Novabiochem (Laufelfingen, Swit- 
zerland). HPLC-grade acetonitrile was from Lab-Scan (Dublin, 
Ireland). Trifluoroacetic acid (TFA), N-methylmorpholine and tri- 
fluoroethanol (TFE) were from Janssen Chimica (Beerse, Belgium). 
Mueller- Hinton broth and Bacto-Agar were purchased from Difco 
Laboratories (Detroit, USA). Melittin and o-nitrophenyl-j%o-galacto- 
pyranoside (ONPG) were from Sigma (St. Louis, USA). All other 
chemicals were of analytical grade. 
2.2. Structure predictlon methods 
Prediction of the secondary structure of CAP18, based on the algo- 
rithms of Garnier et al. [18] and Chou and Fasman [19], was obtained 
using the ‘PeptideStructure’ and ‘Pep’ programs in the GCG and Intel- 
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hgenetics uites, respectively. The same programs were used to predict 
the effect of amino acid substitutions on the structure of the Cl8 
peptide. 
2.3. Peptide synthesis 
Solid-phase peptide synthesis was carried out with a Milligen 9050 
synthesizer using Fmoc-Be-PEG-PS resin (0.13 mmohg). A fivefold 
excess of an equimolar mixture of Fmoc-amino acid, 2-(IH-benzo- 
tnazole-1-yl)-1,1,3,3-tetramethyluronium tetraflouroborate and N-hy- 
droxybenzotriazole, dissolved in dimethylformamide containing N- 
methylmorpholine (tenfold excess), was used for each coupling step. 
Double couplings were carried out for all peptides at residues 5, 12, 16 
and 19. Side-chain protecting groups were as follows: trityl (Asn, Gin), 
t-butyl (Glu), t-butyloxycarbonyl (Lys) and 2,2,5,7,8-pentamethylchro- 
man-6-sulphonyl (Arg). Deprotection/cleavage was carried out with a 
mixture of TFA, phenol, ethanedithiol, methanol and water (92:2:2:2:2) 
for 3 h at room temperature. The free peptides were then filtered, 
repeatedly extracted with ethyl ether, and purified by preparative RP- 
HPLC (1.9 x 30 cm Delta Pak column from Waters, Millipore) eluting 
the column with a O-60% gradient of acetonitrile in 0.05% TFA. The 
homogeneity of each purified peptide was assayed by analytical RP- 
HPLC (0.4 x 25 cm Pep-S column, Pharmacia LKB Biotechnology, 
Uppsala, Sweden) and acid urea-PAGE [20]. 
2.4. Analytical assays 
Peptide concentrations were determined by absorbance at 214 nm as 
reported by Buck et al. [20]. Amino acid analyses and mass determina- 
tions were performed using the Pica-Tag system (Millipore) [21], and 
an LDI 1700 laser desorption mass spectrometer (Linear Scientific Inc., 
Reno, USA), respectively. 
CD spectra were recorded at 20°C on a Jasco J-600 spectropolarime- 
ter with a cell path length of 2 mm. Peptide samples (0.1 mg/ml) were 
dissolved in 5 mM sodium phosphate buffer, pH 7.0, containing 0 to 
50% (vol/vol) TFE and three scans were averaged over the wavelength 
range 19&240 nm. The a-helical content of the peptides was estimated 
with the CONTIN program [22] and by the method of Wu et al. [23], 
using mean molar residue ellipticities of -2000 and -32000 
deg . cm’ . dmol-’ at 222 nm for 0% and 100% helix content, respec- 
tively. 
2 5 Biological actwity assays 
The minimal inhibitory concentration (MIC) of the synthetic peptides 
was determined by a microdilution susceptibility test as previously 
described [24], using the following strains of bacteria: Escherichia coli 
ML-35 and ATCC 25922, Salmonella typhimurium ATCC 14028, Pseu- 
domonas aeruginosa ATCC 27853, Bacillus megaterium (local isolate), 
and Staphylococcus aureus ATCC 25923. To evaluate the bactericidal 
activity, aliquots of the medium taken from peptide-containing wells 
with no visible bacterial growth at the end of the MIC assay, were 
plated on nutrient agar and incubated for 1618 h to allow colony 
counts The minima1 bactericidal concentration (MBC) was defined as 
the lowest concentration of peptide causing at least a 99.9% reduction 
of the number of microorganisms present at the beginning of the MIC 
determination [25]. 
The effect of the synthetic peptides on the permeability of the bacte- 
rial inner membrane was evaluated as previously described [26], by 
followmg the unmasking of cytoplasmic /I-galactosidase activity, using 
ONPG as substrate. For these experiments the lactose permease defi- 
cient, B-galactosidase constitutive E. coli ML-35 strain was used. Total 
/I-galactosidase activity, corresponding to 100% permeabilization, was 
determined with bacteria lysed by ultrasonication. 
The hemolytic activity of the peptides was determined with human 
erythrocytes [27]. The blank was evaluated in the absence of additives 
and 100% hemolysis in the presence of 0.2% Triton X-100. Mehttin was 
used as a positive control, at concentrations between 1 and 10 PM. 
3. Results 
out of 20. Secondary structure prediction studies indi- 
cated a high potential for this region to adopt an CI- 
helical conformation, which clearly shows an amphipa- 
thic nature in a helical wheel projection (Fig. 1). The 
polar face by far dominates the projection, subtending 
an angle of 260” perpendicular to the helical axis, which 
is unusually high compared to known a-helical anti- 
bacterial peptides such as magainins and cecropins, 
where it subtends angles of 100-180” [6,7]. 
By analogy with known antibacterial peptides, the ca- 
tionicity of this sequence, its location after a cathelin-like 
domain, and its predicted a-helical, amphipathic nature 
strongly suggested that the corresponding peptide might 
possess antibacterial activity. This peptide, termed Cl 8, 
was synthesized by the solid-phase method, purified by 
preparative RP-HPLC, and the major peak shown to 
contain a virtually homogeneous peptide by analytical 
RP-HPLC and acid urea-PAGE (not shown). The cor- 
rect structure of the peptide was confirmed by mass de- 
termination (Table 1) and by its amino acid composition 
(not shown). 
The peptide displayed a spectrum typical of an unor- 
dered conformation in 5 mM phosphate buffer, pH 7.0 
(not shown), while at greater than 20% TFE, the increase 
in & and the shape of the spectrum indicated that it had 
acquired a significant level of a-helical conformation 
(Fig. 2, inset). The helical content, calculated with both 
the Contin program [22] and the method of Wu et al. 
[23], is about 55% at 30% TFE. 
The antibacterial activity of Cl 8 was tested by the 
MIC and MBC assays which give the minimal bacteri- 
ostatic and bactericidal concentrations, respectively. 
Three Gram-negative (E. coli, S. typhimurium and t? 
aeruginosa) and two Gram-positive (B. megaterium and 
S. aureus) species were selected as test organisms. The 
results (Table 2) show that Cl8 is active against all of the 
five species at concentrations ranging from 0.5 to 4.0 
PM, with a considerable activity against I? aeruginosa 
(MIC of 0.5 ,uM), a species often resistant o antimicro- 
Table 1 
Amino acid sequences and masses of the synthetic peptide Cl8 and its 
analogues 
Peptide Amino acid sequence Mass 
Measured” Calculated 
1 10 20 
Cl8 GLRKRLRKFRNKIKEKLKKI 2553.72 2553.25 
C18P --------p---p------- 2488.47 2487.14 
C18K -----K------K------- 2583.81 2583.27 
C18AA ----A----------A---- 2412.30 2411.04 
C18A --------*----------- 2476.82 2477.15 
Cl80 --------------Q----_ 2553.07 2552.27 
Inspection of the sequence of CAP1 8, as deduced from 
cDNA [15], showed a highly cationic region between 
residues 106 and 125 (Table l), with 11 cationic residues 
“The mass of each peptide was determined with a laser desorption mass 
spectrometer on samples (l-2 pmol) crystallized under low vacuum in 
the presence of 50 mM sinapinic acid directly on the probe tip of the 
spectrometer. 
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Fig. 1. Helical wheel representation of the C 18 peptide. Charged resi- 
dues are in bold and strongly hydrophobic residues are boxed. The 
asterisks indicate those residues that have been replaced in the Cl8 
analogues. 
bial peptides [24,27,28]. For all strains tested, the MBC 
of Cl 8 is equal to or at most twofold higher than the 
MIC (data not shown), indicating that this peptide is 
bactericidal and not only bacteriostatic. The amphipa- 
thic m-helical structure of Cl8 suggested that it would act 
by permeabilizing biological membranes. Potential dam- 
age to the inner membrane of the E. coli ML-35 strain 
and to the membrane of human erythrocytes was thus 
evaluated. The peptide rapidly increased the inner mem- 
brane permeability of E. coli at a concentration as low 
as 1 PM (Fig. 3). At this concentration, accessibility of 
the cytosolic B-galactosidase to its substrate was already 
evident after 90 s and the reaction reached a steady state 
within 10 min. The rate of reaction was about 50% when 
compared to that of bacteria completely lysed by sonica- 
tion. The kinetics of permeabilization is thus considera- 
bly faster than that reported for the bactenecins Bac5 
and Bac7, which require a tenfold higher concentration 
to obtain comparable results [26], or that for human 
defensins, which is even lower [28]. P-galactosidase activ- 
ity was found in the supernatant after bacterial sedimen- 
tation, indicating that the peptide had induced a suffi- 
cient alteration of the membrane to allow leakage of the 
enzyme. Conversely, Cl 8 did not exert any lytic effect on 
human erythrocytes, even at a concentrations of 50 PM, 
while melittin, a hemolytic peptide known to assume an 
amphipathic a-helical conformation [30], lysed over 90% 
of the erythrocytes at a concentration of 3 ,uM in parallel 
experiments. 
In order to determine how the structure of Cl 8 affects 
its biological activity, five analogues (Table 1) were syn- 
thesized, purified and analyzed in a manner similar to the 
parent peptide. Appropriate amino acid substitutions 
were introduced to vary charge and amphiphilicity or to 
test the importance of individual residues towards the 
activity. 
The analogue C18P (Phe-9 and Ile-13 changed to pro- 
line, see Table 1) was designed to greatly reduce the 
propensity for a-helix formation without affecting 
charge. C18K (Leu-6 and Ile-13 replaced by lysine resi- 
dues) was designed to increase cationicity while reducing 
amphiphilicity. The opposite effect was obtained in 
C18AA by replacing Arg-5 and Lys-16 with alanine. 
Cl SQ, (Glu-15 replaced by glutamine) and Cl 8A (Phe-9 
replaced by alanine), were designed to respectively test 
the role of the single anionic and aromatic residues pres- 
ent in C18. 
The correct identity and homogeneity of the five ana- 
logues were confirmed as for Cl8 (Table 1). As pre- 
dicted, CD spectra of C18P were characteristic of an 
unordered conformation even at 30-50% TFE (Fig. 2), 
indicating a greatly reduced ability to assume an a-heli- 
cal conformation. This peptide was inactive against each 
strain tested up to 64 ,uM (Table 2). C18K also showed 
a reduced propensity for a-helical conformation as com- 
pared to Cl8 (only about 20% helical content at 30% 
TFE, Fig. 2) and showed no antibacterial activity up to 
64 ,uM against most strains (Table 2). Not surprisingly, 
neither C18P nor C18K permeabilized the inner mem- 
brane of E. coli ML-35 at concentrations up to 50 PM 
(Fig. 3) nor did they display hemolytic activity at this 
concentration. 
The hydrophobic surface was increased to subtend an 
angle of 140” in C18AA when compared to that of 100” 
in Cl 8. An analogue with three leucines and a hydropho- 
bic surface subtending an angle of 160” was discarded 
due to low solubility. CD spectra indicated an increased 
tendency of C18AA to adopt an a-helical conformation 
as compared to Cl8 (over 70% a-helix at 30% TFE, Fig. 
2). As reported in Table 2, C18AA showed a two- to 
fourfold increase in antibacterial activity with respect o 
I I I I I I 
200 220 240 
nm 
Fig. 2. Circular dichroism spectra of Cl8 and of its analogues. The 
spectra were measured at a peptide concentration of 0.1 mg/ml in 5 mM 
phosphate buffer, pH 7.0, in the presence of 30% TFE: Cl8 or Cl8Q 
(-), Cl8P (- - -), Cl8K (---_). Cl8AA (- - - -) and C18A (- - -). 
The inset shows the variation of the mean molar residue ellipttcity at 
222 nm (-&) with Increasing TFE concentrations: Cl8 (o), Cl8Q (0). 
Cl8P (a), Cl8K @), Cl8AA (+) and Cl8A (A). 
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the parent peptide, with the exception of I? aeruginosa, 
against which it was sligthly less effective. C18AA per- 
meabilized E. coli ML-35 with a faster kinetics than Cl8 
(reaction rate about 80% that of sonicated bacteria at 
steady state, Fig. 3) while still not exerting any hemolytic 
activity up to a concentration of 50 FM. 
Finally, the role played in determining the activity of 
Cl8 by the single anionic and aromatic residues was 
investigated with C18Q and C18A, respectively (Table 
1). C 1 SQ displayed a structural behaviour and biological 
activities remarkably similar to Cl8 (Figs. 2 and 3, and 
Table 2). Substitution of Phe-9 with alanine in C18A 
appeared to increase the u-helical propensity of this ana- 
logue with respect o the parent peptide (over 80% helical 
content at 30% TFE, Fig. 2). The antibacterial activity 
is sligthly lower than that of C18, as the MIC and MBC 
values doubled for most strains (Table 2). A twentyfold 
greater concentration was however required to give a 
~~eabilization behaviour comparable to that of the 
parent peptide (Fig. 3, trace d vs. trace f). At 1 ,uM (Fig. 
3, trace c), a similar steady state was observed only after 
fourty minutesThus the presence of the aromatic residue 
appears to affect the kinetics rather than the degree of 
permeabilization. Neither Cl 8Q nor Cl 8A displayed he- 
molytic activity up to a concentration of 50 ,uM. 
4. Discussion 
The present study, based on a secondary structure 
prediction/peptide synthesis approach, has allowed the 
identification of a primary antimicrobial domain in 
CAP18 from rabbit leukocytes. Results show that the 
corresponding peptide, Cl 8, displays a confo~ational 
change from an unordered to a predominantly a-helical 
Table 2 
Antibacterial activity of Cl 8 and of its analogues 
Orgamsm and strain MIC (uM) 
Cl8 Cl8P Cl8K Cl8AA C18A Cl8Q 
~scherichja coli ML 35 2 >64 >64 0.5 4 2 
Escherichia colz 4 =-64 >64 2 4 4 
ATCC 25922 
Salmonella typhimurium 2 ~64 >64 0.5 16 2 
ATCC 14028 
Pseudomonas aeruginosa 0.5 >64 >64 2 1 0.5 
ATCC 27853 
Bacillus megaterium 4 > 64 64 2 8 4 
(local isolate) 
Staphyla&oc~~ aureus 4 >64 =-64 2 8 4 
ATCC 25923 
MIC was defined as the lowest concentration of peptide preventing 
visible growth after 18 h incubation at 37°C in Mueller-Hinton broth 
1241. Results, determined with approximately 1.5 x lo5 colony forming 
units/ml, are the mean of at least six independent determinations with 
a divergence of not more than one MIC value with respect to those 
reported here. 
a 
Fig. 3. Kinetics of permeabilization of E. coli ML-35 inner membrane 
by Cl8 and its analogues. Permeabilization was determined by follow- 
ing the unmasking of cytoplasmic /I-galactosidase activity spectro- 
photomet~c~ly at 405 nm. Bacteria (about 10’ colony forming units/ 
ml) were suspended in 10 mM sodium phosphate buffer, pH 7.5, con- 
taining 100 mM NaCl and 1.5 mM substrate. Trace a, untreated bacte- 
ria; trace b, Cl8P or C18K at 50pM; trace c, Cl8A at 1 ,uM; trace d, 
C18A at 20pM; trace e, C18Q at 1 PM; trace f, Cl8 at 1 PM; trace g, 
C18AA at 1 PM. The arrow indicates the time of addition of peptides. 
Results are representative of three very similar, independent experi- 
confo~ation when the polarity of the environment is 
decreased, a behaviour typical of an amphipathic helix, 
and exerts a potent antibacterial activity against Gram- 
negative and Gram-positive microorganisms. 
Amphipathic helices have been observed for a wide 
variety of biologically active peptides whose function is 
related to the binding of lipids and cell membranes [31], 
and is a feature colon to many antimicrobial peptides, 
such as insect cecropins 261, amphibian magainins [7,32], 
PGLa [32] and dermaseptin [33], and other membrane 
interacting peptides, such as melittin [30]. The Cl8 pep- 
tide here described, with the analogous PMAP-36(1-20), 
derived from a precursor cloned from pig myeloid cells 
(Storici, P. et al., unpublished), and cecropin Pl from pig 
intestine [34,35] show that the ~phipathic a-helix is a 
confo~ational motif represented also among the mam- 
malian antibacterial peptides. It is interesting to note 
that Cl8 and PMAP-36(1-20), as opposed to insect and 
amphibian peptides, are characterized by an unusually 
high content of cationic residues (55560%) and a large 
hydrophilic face of the helix, which points to the consid- 
erable flexibility in the make up of a-helices with anti- 
bacterial activity. 
Membrane pe~eabilization experiments show that 
Cl 8 rapidly permeabilizes the inner membrane of the E. 
co& ML-35 strain. As damage to the membrane is suffi- 
cient to allow the leakage of a relatively large enzyme, 
it is likely that this damage is the primary event in killing 
bacteria. The importance of a-helical conformation in 
the antibacterial and membrane permeabilizing activities 
112 
in C 18 is shown by the ineffectiveness of analogues in 
which this conformation is disrupted or greatly reduced 
(C18P and C18K). The analogue C18AA displays a 
greater antibacterial activity and a faster kinetics of per- 
meabilization, so that a moderate increase in amphipath- 
icity at the expense of charge can potentiate the activity 
of the parent peptide. Conversely, replacement of the 
only aromatic residue in C18A results in a much slower 
kinetics of permeabilization, while the degree of permea- 
bilization at steady state and the antibacterial activity are 
not greatly affected. In this respect, aromatic residues are 
nearly always present in a-helical antibacterial peptides, 
and have been shown to play an important role for activ- 
ity. In fact, replacement of Trp-2 of cecropin A with Glu, 
but not with Phe, results in a sharp drop in antibacterial 
activity [36], as does the replacement of Phe-5 and Phe-12 
with Thr or Ser in magainin 2 [37]. While C18A, in which 
Phe-9 is replaced with the hydrophobic residue Ala, does 
not show the dramatic decrease in antibacterial activity 
of the above cases, it suggests that the presence of an 
aromatic residue is important in mediating the interac- 
tion with bacterial membranes. 
We have observed that a-helical antibacterial peptides, 
such as magainins and cecropins, very often contain a 
glutamic acid residue. This induced us to test whether 
this residue had any significant role in the biological 
activity of C18, by synthesizing the Cl8Q analogue. Our 
results indicate that it is replaceable by glutamine with- 
out any measurable ffect, at least as far as helix forma- 
tion, antibacterial activity and membrane permeabiliza- 
tion kinetics or specificity are concerned. 
Our study shows how simple considerations based on 
sequence homology (presence of a cathelin-like pro re- 
gion) and structure prediction analysis, followed by pep- 
tide synthesis, have allowed the successful1 identification 
of an antibacterial sequence in the LPS binding polypep- 
tide CAP18. Moreover, it has provided information on 
structure/activity relationships which may be useful in 
the design of novel antibiotic peptides. 
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